Renal denervation: What happened, and why?

REFERENCES

1. ↵
   1. Bhatt DL,
   2. Kandzari DE,
   3. O’Neill WW,
   4. et al.
   5. for the SYMPLICITY HTN-3 Investigators

   . A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370:1393–1401.

   OpenUrlCrossRefPubMed
2. ↵
   1. Symplicity HTN-2 Investigators
   2. Esler MD,
   3. Krum H,
   4. Sobotka PA,
   5. Schlaich MP,
   6. Schmieder RE,
   7. Bohm M

   . Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet 2010; 376:19031909.

   OpenUrl
3. ↵
   1. Bunte MC,
   2. Infante de Oliveira E,
   3. Shishehbor MH

   . Endovascular treatment of resistant and uncontrolled hypertension: therapies on the horizon. JACC Cardiovasc Interv 2013; 6:1–9.

   OpenUrlAbstract/FREE Full Text
4. ↵
   1. Thomas G,
   2. Shishehbor MH,
   3. Bravo EL,
   4. Nally JV

   . Renal denervation to treat resistant hypertension: guarded optimism. Cleve Clin J Med 2012; 79:501–510.

   OpenUrlAbstract/FREE Full Text
5. ↵
   1. Shishehbor MH,
   2. Bunte MC

   . Anatomical exclusion for renal denervation: are we putting the cart before the horse? JACC Cardiovasc Interv 2014; 7:193–194.

   OpenUrlFREE Full Text
6. ↵
   1. Bhatt DL,
   2. Bakris GL

   . The promise of renal denervation. Cleve Clin J Med 2012; 79:498–500.

   OpenUrlFREE Full Text
7. ↵
   1. Bunte MC

   . Renal sympathetic denervation for refractory hypertension. Lancet 2011; 377:1074; author reply 1075.

   OpenUrlPubMed
8. ↵
   1. Mahfoud F,
   2. Luscher TF,
   3. Andersson B,
   4. et al
   5. European Society of Cardiology

   . Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013; 34:2149–2157.

   OpenUrlCrossRefPubMed
9. ↵
   1. Schlaich MP,
   2. Schmieder RE,
   3. Bakris G,
   4. et al

   . International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol 2013; 62:2031–2045.

   OpenUrlFREE Full Text
10. ↵
    1. Azizi M,
    2. Sapoval M,
    3. Gosse P,
    4. et al
    5. Renal Denervation for Hypertension (DENERHTN) investigators

    . Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015; 385:19571965.

    OpenUrl
11. ↵
    1. Rosa J,
    2. Widimsky P,
    3. Tousek P,
    4. et al

    . Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension 2015; 65:407–413.

    OpenUrlCrossRef
12. ↵
    1. Williams B,
    2. MacDonald TM,
    3. Morant S,
    4. et al
    5. British Hypertension Society’s PATHWAY Studies Group

    . Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double blind, crossover trial. Lancet 2015; 386:2059–2068.

    OpenUrlCrossRefPubMed
13. ↵
    1. Sakakura K,
    2. Ladich E,
    3. Cheng Q,
    4. et al

    . Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol 2014; 64:635–643.

    OpenUrlFREE Full Text
14. ↵
    1. Mahfoud F,
    2. Edelman ER,
    3. Bohm M

    . Catheter-based renal denervation is no simple matter: lessons to be learned from our anatomy? J Am Coll Cardiol 2014; 64:644–646.

    OpenUrlFREE Full Text
15. ↵
    1. Id D,
    2. Kaltenbach B,
    3. Bertog SC,
    4. et al

    . Does the presence of accessory renal arteries affect the efficacy of renal denervation? JACC Cardiovasc Interv 2013; 6:1085–1091.

    OpenUrlCrossRefPubMed
16. ↵
    1. Jin Y,
    2. Jacobs L,
    3. Baelen M,
    4. et al
    5. Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug-Resistant Hypertension (Inspired) Investigators

    . Rationale and design of the Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug-Resistant Hypertension (INSPiRED) trial. Blood Press 2014; 23:138–146.

    OpenUrlCrossRefPubMed
17. ↵
    1. ClinicalTrialsgov

    . Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN: REINFORCE). https://clinicaltrials.gov/ct2/show/NCT02392351?term=REDUCE-HTN%3A+REINFORCE&rank=1. Accessed August 3, 2017.
18. ↵
    1. Fischell TA,
    2. Ebner A,
    3. Gallo S,
    4. et al

    . Transcatheter alcohol-mediated perivascular renal denervation with the peregrine system: first-inhuman experience. JACC Cardiovasc Interv 2016; 9:589–598.

    OpenUrlCrossRef
19. ↵
    1. ClinicalTrialsgov

    . Sham controlled study of renal denervation for subjects with uncontrolled hypertension (WAVE_IV) (NCT02029885). https://clinicaltrials.gov/ct2/show/results/NCT02029885. Accessed August 3, 2017.
20. ↵
    1. Mahfoud F,
    2. Bohm M,
    3. Azizi M,
    4. et al

    . Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J 2015; 36:2219–2227.

    OpenUrlCrossRefPubMed
21. ↵
    1. Kandzari DE,
    2. Kario K,
    3. Mahfoud F,
    4. et al

    . The SPYRAL HTN Global Clinical Trial Program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Heart J 2016; 171:82–91.

    OpenUrlPubMed
22. ↵
    1. ClinicalTrialsgov

    . A Study of the ReCor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN). https://clinicaltrials.gov/ct2/show/NCT02649426?term=RADIANCE&rank=3. Accessed August 3, 2017.